3
Key Recommendations
The following are general recommendations that should be followed. For
specific CAR T-related toxicities management, please see Tables 1–7.
It is recommended that clinicians manage toxicities as follows:
➤ Management of short-term toxicities associated with CAR T-cells
begins with supportive care for most patients, but may require
pharmacological interventions for those without adequate response.
➤ Management of patients with prolonged or severe CAR T-cell-
associated CRS includes treatment with tocilizumab ± a
corticosteroid.
➤ Based on the potential for rapid decline, patients with moderate
to severe ICANS should be managed with corticosteroids and best
supportive care.
➤ Steroids should be rapidly tapered once symptoms improve to Grade 1.
All recommendations in this guideline are consensus based with benefits outweighing
harms.
